Long-Term Responders After Brentuximab Vedotin: Single-Center Experience on Relapsed and Refractory Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma Patients

Gandolfi Letizia; Pellegrini Cinzia; Casadei Beatrice; Stefoni Vittorio; Broccoli Alessandro; Tonialini Lorenzo; Morigi Alice; Argnani Lisa; Zinzani Pier Luigi

首页> 外文期刊>The oncologist >Long-Term Responders After Brentuximab Vedotin: Single-Center Experience on Relapsed and Refractory Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma Patients

【24h】

Long-Term Responders After Brentuximab Vedotin: Single-Center Experience on Relapsed and Refractory Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma Patients

机译：Brentuximab Vedotin治疗后的长期反应者：复发和难治性霍奇金淋巴瘤和间变性大细胞淋巴瘤患者的单中心经验

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Background. Brentuximab vedotin (BV) has shown high overall response rate in refractory/relapsed Hodgkin lymphoma (HL) and systemic anaplastic large cell lymphoma (sALCL) with reported long-term response duration in clinical trials, but few data are available regarding its role in long-term outcomes in real life.

机译：背景。 Brentuximab vedotin（BV）在难治性/复发性霍奇金淋巴瘤（HL）和系统性间变性大细胞淋巴瘤（sALCL）中显示出较高的总体缓解率，在临床试验中报告了长期缓解持续时间，但关于其长期作用的数据很少现实生活中的长期结果。

著录项

来源
《The oncologist》 |2016年第12期|共6页
作者
Gandolfi Letizia; Pellegrini Cinzia; Casadei Beatrice; Stefoni Vittorio; Broccoli Alessandro; Tonialini Lorenzo; Morigi Alice; Argnani Lisa; Zinzani Pier Luigi;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词
Brentuximab vedotin; Long-term response; Real life; Hodgkin lymphoma; Systemic anaplastic large cell lymphoma;

机译：布伦妥昔单抗vedotin;长期反应;现实生活;霍奇金淋巴瘤;系统间变性大细胞淋巴瘤;

相似文献

外文文献
中文文献
专利

1. Long-Term Responders After Brentuximab Vedotin: Single-Center Experience on Relapsed and Refractory Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma Patients [J] . Gandolfi Letizia, Pellegrini Cinzia, Casadei Beatrice, The oncologist . 2016,第12期

机译：Brentuximab Vedotin治疗后的长期反应者：复发和难治性霍奇金淋巴瘤和间变性大细胞淋巴瘤患者的单中心经验
2. Long-Term Responders After Brentuximab Vedotin: Single-Center Experience on Relapsed and Refractory Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma Patients [J] . Letizia Gandolfi, Cinzia Pellegrini, Beatrice Casadei, The oncologist . 2016,第12期

机译：Brentuximab Vedotin治疗后的长期反应者：复发和难治性霍奇金淋巴瘤和间变性大细胞淋巴瘤患者的单中心经验
3. Experience of brentuximab vedotin in relapsed/refractory Hodgkin lymphoma and relapsed/refractory systemic anaplastic large-cell lymphoma in the Named Patient Program: Review of the literature [J] . Zinzani P. L., Sasse S., Radford J., Critical reviews in oncology/hematology . 2015,第3期

机译：brentuximab vedotin在指定患者计划中的复发/难治性霍奇金淋巴瘤和复发/难治性系统间变性大细胞淋巴瘤的经验：文献综述
4. Functional characterization of ubiquitination profile changes induced by oncogenic protein NPM-ALK in ALK~(+) anaplastic large cell lymphoma cells [C] . Fang Wu, Peng Wang, Raymond Lai, American Society for Mass Spectrometry Conference on Mass Spectrometry and Allied Topics . 2010

机译：致癌蛋白NPM-ALK诱导ubiquitination曲线变化的功能表征Ala1（+）促进大细胞淋巴瘤细胞
5. Safety and Efficacy of the Immunomodulatory Drug (IMiD) Lenalidomide in Patients with Lymphoma: Development of RU051417I - Phase I/II Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Lenalidomide [R2-ICE] in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL). [D] . Kasi, Pashtoon Murtaza. 2018

机译：免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性：RU051417I-R-ICE（利妥昔单抗-异环磷酰胺-卡铂-依托泊苷）与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤（DLBCL）。
6. Long-Term Responders After Brentuximab Vedotin: Single-Center Experience on Relapsed and Refractory Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma Patients [O] . Letizia Gandolfi, Cinzia Pellegrini, Beatrice Casadei, 2016

机译：布伦妥昔单抗Vedotin后的长期反应：复发和难治性霍奇金淋巴瘤和间变性大细胞淋巴瘤患者的单中心经验
7. Hematopoietic Stem Cell Transplantation and Brentuximab Vedotin for Patients with Relapsed or Refractory Hodgkin Lymphoma and Systemic Anaplastic Large-Cell Lymphoma [O] . Kenichi Ishizawa, Tomoko Yanai 2019

机译：造血干细胞移植和Brentuximab Vedotin对复发或难治性Hodgkin淋巴瘤和全身包水性大细胞淋巴瘤的患者

Long-Term Responders After Brentuximab Vedotin: Single-Center Experience on Relapsed and Refractory Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma Patients

摘要

著录项

相似文献

相关主题

期刊订阅